• Education
    • Higher Education
    • Scholarships & Grants
    • Online Learning
    • School Reforms
    • Research & Innovation
  • Lifestyle
    • Travel
    • Food & Drink
    • Fashion & Beauty
    • Home & Living
    • Relationships & Family
  • Technology & Startups
    • Software & Apps
    • Startup Success Stories
    • Startups & Innovations
    • Tech Regulations
    • Venture Capital
    • Artificial Intelligence
    • Cybersecurity
    • Emerging Technologies
    • Gadgets & Devices
    • Industry Analysis
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy
Today Headline
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
Today Headline
No Result
View All Result
Home Science & Environment Medical Research

Substantial portion of cancer patients in early trials access drugs that are later approved, study finds

February 25, 2025
in Medical Research
Reading Time: 3 mins read
A A
0
clinical trial
2
SHARES
5
VIEWS
Share on FacebookShare on Twitter


clinical trial
Credit: Pixabay/CC0 Public Domain

A paper in the Journal of the National Cancer Institute finds that almost 20% of patients in middle-stage cancer drug trials receive treatment that eventually proves effective enough to get FDA approval. This may have important implications for drug development and clinical trial recruitment.

The development of new medications typically has three stages. In Phase I trials, researchers assess drugs for safety and dosing (“What is the best tolerated dose for the patient?”). Phase II clinical trials determine whether a new drug shows signs of efficacy (“How much does the drug reduce disease?”).

Drugs showing promise in Phase II are then evaluated in Phase III trials, which are conducted at multiple centers with at least several hundred patients and often inform whether the FDA approves of the drug for use as treatment.

However, unlike initial Phase I trials, all patients in Phase II trials receive drugs at the doses intended for routine use with the expectation the drug will be active and beneficial, though this is unknown from prior experience.

With more patients treated at an active dose, a drug is more likely to have side effects. Therefore, the question of efficacy in Phase II trials is an important consideration for patients wishing to receive newer treatments.

The aim of the study was to estimate the proportion of cancer patients in Phase II trials who receive new interventions that are later deemed safe and effective and approved by the FDA.

The researchers here identified 2,730 Phase II clinical trials, beginning between Nov. 2012 and Nov. 2015, 1,154 of which met eligibility and 400 of which were randomly sampled for inclusion. These Phase II trials had a total patient enrollment of 25,002 patient-participants in 608 specific cohorts or arms (including control arms) which tested 332 drugs. Twenty-five drugs were evaluated in more than 10 trials, 155 in two to 10 trials, and 152 in one trial only.

The investigation found that the FDA later approved 71 drug regimens in the tested indication, and one in six (16%) patients in Phase II trials received such regimens. However, the authors of the study point out that accessing a drug that later gets FDA approval doesn’t necessarily mean the patient will benefit.

“Keep in mind that approved drugs don’t work for every person. For many FDA-approved cancer drugs, only half to a tenth of patients meaningfully benefit,” said the paper’s lead author, Charlotte Ouimet.

The authors of the study say that these findings give patients important information on expectations for Phase II trials. Most patients who enroll in Phase II have advanced cancers that lack standard treatment options. Many such patients are likely to regard a 16% probability of receiving a drug that later secures FDA approval for their condition as favorable odds.

“If you’re a cancer patient and you are invited into a Phase II trial, keep in mind that five of six patients get treatments that do not go on to approval,” said Jonathan Kimmelman, another author. “Just the same, your odds are dramatically better than they would be for a Phase I trial.”

“Your odds of receiving an effective drug in Phase II are quite a bit higher than for Phase I trials. But probably still a lot lower than for Phase III trials, where the odds are probably more like one in three,” Kimmelman continued.

More information:
Jonathan Kimmelman et al, Proportion of Patients in Phase 2 Oncology Trials Receiving Treatments that are Ultimately Approved, Journal of the National Cancer Institute (2025). DOI: 10.1093/jnci/djaf013

Provided by
Oxford University Press


Citation:
Substantial portion of cancer patients in early trials access drugs that are later approved, study finds (2025, February 25)
retrieved 25 February 2025
from https://medicalxpress.com/news/2025-02-substantial-portion-cancer-patients-early.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.



clinical trial
Credit: Pixabay/CC0 Public Domain

A paper in the Journal of the National Cancer Institute finds that almost 20% of patients in middle-stage cancer drug trials receive treatment that eventually proves effective enough to get FDA approval. This may have important implications for drug development and clinical trial recruitment.

The development of new medications typically has three stages. In Phase I trials, researchers assess drugs for safety and dosing (“What is the best tolerated dose for the patient?”). Phase II clinical trials determine whether a new drug shows signs of efficacy (“How much does the drug reduce disease?”).

Drugs showing promise in Phase II are then evaluated in Phase III trials, which are conducted at multiple centers with at least several hundred patients and often inform whether the FDA approves of the drug for use as treatment.

However, unlike initial Phase I trials, all patients in Phase II trials receive drugs at the doses intended for routine use with the expectation the drug will be active and beneficial, though this is unknown from prior experience.

With more patients treated at an active dose, a drug is more likely to have side effects. Therefore, the question of efficacy in Phase II trials is an important consideration for patients wishing to receive newer treatments.

The aim of the study was to estimate the proportion of cancer patients in Phase II trials who receive new interventions that are later deemed safe and effective and approved by the FDA.

The researchers here identified 2,730 Phase II clinical trials, beginning between Nov. 2012 and Nov. 2015, 1,154 of which met eligibility and 400 of which were randomly sampled for inclusion. These Phase II trials had a total patient enrollment of 25,002 patient-participants in 608 specific cohorts or arms (including control arms) which tested 332 drugs. Twenty-five drugs were evaluated in more than 10 trials, 155 in two to 10 trials, and 152 in one trial only.

The investigation found that the FDA later approved 71 drug regimens in the tested indication, and one in six (16%) patients in Phase II trials received such regimens. However, the authors of the study point out that accessing a drug that later gets FDA approval doesn’t necessarily mean the patient will benefit.

“Keep in mind that approved drugs don’t work for every person. For many FDA-approved cancer drugs, only half to a tenth of patients meaningfully benefit,” said the paper’s lead author, Charlotte Ouimet.

The authors of the study say that these findings give patients important information on expectations for Phase II trials. Most patients who enroll in Phase II have advanced cancers that lack standard treatment options. Many such patients are likely to regard a 16% probability of receiving a drug that later secures FDA approval for their condition as favorable odds.

“If you’re a cancer patient and you are invited into a Phase II trial, keep in mind that five of six patients get treatments that do not go on to approval,” said Jonathan Kimmelman, another author. “Just the same, your odds are dramatically better than they would be for a Phase I trial.”

“Your odds of receiving an effective drug in Phase II are quite a bit higher than for Phase I trials. But probably still a lot lower than for Phase III trials, where the odds are probably more like one in three,” Kimmelman continued.

More information:
Jonathan Kimmelman et al, Proportion of Patients in Phase 2 Oncology Trials Receiving Treatments that are Ultimately Approved, Journal of the National Cancer Institute (2025). DOI: 10.1093/jnci/djaf013

Provided by
Oxford University Press


Citation:
Substantial portion of cancer patients in early trials access drugs that are later approved, study finds (2025, February 25)
retrieved 25 February 2025
from https://medicalxpress.com/news/2025-02-substantial-portion-cancer-patients-early.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.


Tags: Health ResearchHealth Research NewsHealth ScienceMedicine ResearchMedicine Research NewsMedicine Science
Previous Post

Rudy Giuliani satisfies judgment in defamation case brought by former Georgia election workers

Next Post

Sri Lanka’s CTC says revenue down in Dec 2024 quarter amid smuggling todayheadline

Related Posts

hip

Using testosterone gel to treat women recovering from hip fractures provides no added benefits, clinical trial finds

May 24, 2025
4
3D-printed device advances human tissue modeling

3D-printed device enables precise modeling of complex human tissues in the lab

May 24, 2025
10
Next Post

Sri Lanka’s CTC says revenue down in Dec 2024 quarter amid smuggling todayheadline

  • Trending
  • Comments
  • Latest
Family calls for change after B.C. nurse dies by suicide after attacks on the job

Family calls for change after B.C. nurse dies by suicide after attacks on the job

April 2, 2025
Pioneering 3D printing project shares successes

Product reduces TPH levels to non-hazardous status

November 27, 2024

Hospital Mergers Fail to Deliver Better Care or Lower Costs, Study Finds todayheadline

December 31, 2024

Police ID man who died after Corso Italia fight

December 23, 2024
Harris tells supporters 'never give up' and urges peaceful transfer of power

Harris tells supporters ‘never give up’ and urges peaceful transfer of power

0
Des Moines Man Accused Of Shooting Ex-Girlfriend's Mother

Des Moines Man Accused Of Shooting Ex-Girlfriend’s Mother

0

Trump ‘looks forward’ to White House meeting with Biden

0
Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

0
Water begins flowing to create new wetlands at shrinking Salton Sea

Water begins flowing to create new wetlands at shrinking Salton Sea

May 24, 2025

To meet Trump’s goals, the arsenal of democracy must deliver on time

May 24, 2025
At Cannes, Fukada spotlights J-pop’s ban on idol romance

At Cannes, Fukada spotlights J-pop’s ban on idol romance

May 24, 2025
Montreal police arrest five in distraction theft probe targeting seniors, jewelry - Montreal

Montreal police arrest five in distraction theft probe targeting seniors, jewelry – Montreal

May 24, 2025

Recent News

Water begins flowing to create new wetlands at shrinking Salton Sea

Water begins flowing to create new wetlands at shrinking Salton Sea

May 24, 2025
4

To meet Trump’s goals, the arsenal of democracy must deliver on time

May 24, 2025
3
At Cannes, Fukada spotlights J-pop’s ban on idol romance

At Cannes, Fukada spotlights J-pop’s ban on idol romance

May 24, 2025
6
Montreal police arrest five in distraction theft probe targeting seniors, jewelry - Montreal

Montreal police arrest five in distraction theft probe targeting seniors, jewelry – Montreal

May 24, 2025
3

TodayHeadline is a dynamic news website dedicated to delivering up-to-date and comprehensive news coverage from around the globe.

Follow Us

Browse by Category

  • Africa
  • Asia
  • Basketball
  • Business & Finance
  • Climate Change
  • Crime & Justice
  • Economic Policies
  • Elections
  • Entertainment
  • Entrepreneurship
  • Environmental Policies
  • Europe
  • Football
  • Gadgets & Devices
  • Health
  • Medical Research
  • Mental Health
  • Middle East
  • Motorsport
  • Olympics
  • Politics
  • Public Health
  • Relationships & Family
  • Science & Environment
  • Software & Apps
  • Space Exploration
  • Sports
  • Stock Market
  • Technology & Startups
  • Tennis
  • Travel
  • Uncategorized
  • Us & Canada
  • Wildlife & Conservation
  • World News

Recent News

Water begins flowing to create new wetlands at shrinking Salton Sea

Water begins flowing to create new wetlands at shrinking Salton Sea

May 24, 2025

To meet Trump’s goals, the arsenal of democracy must deliver on time

May 24, 2025
  • Education
  • Lifestyle
  • Technology & Startups
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy

© 2024 Todayheadline.co

Welcome Back!

OR

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Business & Finance
  • Corporate News
  • Economic Policies
  • Entrepreneurship
  • Market Trends
  • Crime & Justice
  • Court Cases
  • Criminal Investigations
  • Cybercrime
  • Legal Reforms
  • Policing
  • Education
  • Higher Education
  • Online Learning
  • Entertainment
  • Awards & Festivals
  • Celebrity News
  • Movies
  • Music
  • Health
  • Fitness & Nutrition
  • Medical Breakthroughs
  • Mental Health
  • Pandemic Updates
  • Lifestyle
  • Fashion & Beauty
  • Food & Drink
  • Home & Living
  • Politics
  • Elections
  • Government Policies
  • International Relations
  • Legislative News
  • Political Parties
  • Africa
  • Asia
  • Europe
  • Middle East
  • Artificial Intelligence
  • Cybersecurity
  • Emerging Technologies
  • Gadgets & Devices
  • Industry Analysis
  • Basketball
  • Football
  • Motorsport
  • Olympics
  • Climate Change
  • Environmental Policies
  • Medical Research
  • Science & Environment
  • Space Exploration
  • Wildlife & Conservation
  • Sports
  • Tennis
  • Technology & Startups
  • Software & Apps
  • Startup Success Stories
  • Startups & Innovations
  • Tech Regulations
  • Venture Capital
  • Uncategorized
  • World News
  • Us & Canada
  • Public Health
  • Relationships & Family
  • Travel
  • Research & Innovation
  • Scholarships & Grants
  • School Reforms
  • Stock Market
  • TV & Streaming
  • Advertise with Us
  • Privacy & Policy
  • About us
  • Contact

© 2024 Todayheadline.co